Degarelix Injection

The core use of Degarelix is for adult male patients with advanced hormone dependent prostate cancer who require androgen deprivation therapy (ADT). It is currently the only approved long-acting GnRH antagonist that directly competes to block pituitary GnRH receptors, rapidly, stably, and long-term inhibiting testosterone to castration levels (≤ 0.5ng/ml), fundamentally blocking the driving effect of androgens on prostate cancer cells, achieving the core treatment goals of inhibiting tumor proliferation, reducing tumor volume, alleviating clinical symptoms, and prolonging survival. As a revolutionary ADT drug, the basic use value of degarelix is focused on three core advantages, completely solving the fatal defects of traditional GnRH agonists (leuprorelin, goserelin):

Rapid castration, reaching the standard within 3 days: Within 3 days after medication, 96% of patients' testosterone levels drop to castration levels (≤ 0.5ng/ml), and 100% reach the standard within 1 month, while traditional agonists only reach 80% after 2-4 weeks. This can quickly control tumor progression, alleviate clinical symptoms, and seize opportunities for subsequent treatment.

LAPC is a stage T3-T4 prostate cancer with no distant metastasis, large tumor volume, and difficult to completely remove by surgery. The 5-year survival rate is only 40-50%. The use of ticagrelor for neoadjuvant ADT (before radical treatment) and adjuvant ADT (after radical treatment) is a key link in the comprehensive treatment of LAPC. Core objectives: Reduce tumor volume, lower clinical staging, minimize lymph node metastasis, lower surgical difficulty, and improve radical resection rate;
Application value: Degarelix rapidly reduces tumor volume by 50% within 2 months, significantly better than the 30% reduction of traditional agonists, creating optimal conditions for curative surgery/radiotherapy, especially suitable for high-risk patients with tumor volume>50cm ³ and T4 stage invasion of surrounding tissues.
Core objectives: eliminate small residual lesions, reduce the risk of recurrence, and prolong disease-free survival (DFS);
Application value: Degarelix has long-term stable castration, with a 5-year DFS of 75%, significantly higher than the 60% of traditional agonists, and a 40% reduction in recurrence rate. It is suitable for all high-risk LAPC patients (Gleason ≥ 8, PSA ≥ 20ng/ml, T3-T4 stage).

BCR is a prostate cancer with no clinically visible metastases after radical surgery/radiotherapy, but with a sustained increase in PSA levels (≥ 0.2ng/ml), with a 5-year metastasis rate of 30-50%. Degarelix is the preferred intervention for salvage ADT in BCR patients.
Rapid inhibition of PSA: PSA decreases by 80% within one month, preventing sustained increase in PSA;
Delaying distant metastasis: Long term control of tumor activity, reducing the risk of bone and lymph node metastasis;
Extended metastasis free survival: The 5-year metastasis free survival rate is 65%, significantly better than traditional agonists.
Suitable for all prostate cancer patients who experience biochemical recurrence after radical treatment, especially for high-risk populations with PSA doubling time<6 months, Gleason ≥ 7 points, and PSA>1ng/ml at the time of recurrence. It can effectively delay disease progression and avoid early metastasis.